Loss of response to infliximab is common amongst patients with inflammatory bowel disease and varies according to definition
Background: Loss of response (LOR) to infliximab (IFX) is common amongst patients with inflammatory bowel disease (IBD); however, there is heterogeneity as to how LOR is defined. Roda et al. (2016) suggest that LOR may be defined according to recurrence of symptoms, or alternatively only when there is objective evidence of recurrent disease, or only when a change in biologic was instituted.1 Aims: To assess the rate of LOR to IFX amongst patients with IBD treated at a tertiary referral...[Show more]
|Collections||ANU Research Publications|
|Source:||Journal of Gastroenterology and Hepatology|
|Access Rights:||Free Access via publisher website|
|01_Sivanes_Loss_of_response_to_infliximab_2016.pdf||1.75 MB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.